Lannett Co. Inc., owner of Cody Labs, became further bogged down by generic drug price-fixing charges when LCI and two employees were named in a civil lawsuit Friday.
Some stock market analysts, monitoring court cases that accuse multiple generic drug pharmaceutical companies of price fixing, are predicting harsh consequences for LCI.
Fines and management turnover are inevitable, Seeking Alpha predicted on Monday on its stock market insight and financial analysis website.
The Philadelphia-based generic drug company develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications. In addition to Cody Labs, it owns Silarx Pharmaceuticals in Carmel, N.Y., and Kremers Urban Pharmaceuticals in Seymour, Ind.
On Friday, the State of Connecticut, along with 40 other states filed a 510-page amended complaint against a series of generic drug makers and their current andClick here to view the full story